Actelion launches Phase III MS test for ponesimod

Buoyed by the success of its PAH franchise, Switzerland's Actelion says it has begun a Phase III study of its in-house drug ponesimod for multiple sclerosis. And planning is underway to push a Phase II for ponesimod in chronic graft versus host disease. The Phase III will recruit 1,100 patients. "Our ongoing success in the field of PAH is enabling us to pursue the second element of our strategy and take action now to build an additional specialty franchise in the field of immunology," says CEO Jean-Paul Clozel. Release